The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer
Open accessAbstract
Background The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice. Methods We used a new bioinformatics approach to search for biomarkers of colon epithelial differentiation across gene-expression arrays and then ranked candidate genes according to the availability of clinical-grade diagnostic assays. With the use of subgroup analysis involving independent and retrospective cohorts of patients with stage II or stage III colon cancer, the top candidate gene was tested for its association with disease-free survival and a benefit from adjuvant chemotherapy. Results The transcription factor CDX2 ranked first in our screening test. A group of 87 of 2115 tumor samples (4.1%) lacked CDX2 expression. In the discovery data set, which included 466 patients, the rate of 5-year disease-free survival was lower among the 32 patients (6.9%) with CDX2-negative colon cancers than among the 434 (93.1%) with CDX2-positive colon cancers (hazard ratio for disease recurrence, 3.44; 95% confidence interval [CI], 1.60 to 7.38; P=0.002). In the validation data set, which included 314 patients, the rate of 5-year disease-free survival was lower among the 38 patients (12.1%) with CDX2 protein-negative colon cancers than among the 276 (87.9%) with CDX2 protein-positive colon cancers (hazard ratio, 2.42; 95% CI, 1.36 to 4.29; P=0.003). In both these groups, these findings were independent of the patient's age, sex, and tumor stage and grade. Among patients with stage II cancer, the difference in 5-year disease-free survival was significant both in the discovery data set (49% among 15 patients with CDX2-negative tumors vs. 87% among 191 patients with CDX2-positive tumors, P=0.003) and in the validation data set (51% among 15 patients with CDX2-negative tumors vs. 80% among 106 patients with CDX2-positive tumors, P=0.004). In a pooled database of all patient cohorts, the rate of 5-year disease-free survival was higher among 23 patients with stage II CDX2-negative tumors who were treated with adjuvant chemotherapy than among 25 who were not treated with adjuvant chemotherapy (91% vs. 56%, P=0.006). Conclusions Lack of CDX2 expression identified a subgroup of patients with high-risk stage II colon cancer who appeared to benefit from adjuvant chemotherapy. (Funded by the National Comprehensive Cancer Network, the National Institutes of Health, and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005
Phenotypic characterization of human colorectal cancer stem cells
Dalerba, P., Dylla, S. J., Park, I.-K., Liu, R., Wang, X., Cho, R. W., Hoey, T., Gurney, A., Huang, E. H., Simeone, D. M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0703478104 · Cited by 2,184
Self-citationSystemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): Explanation and Elaboration
Altman, D. G., McShane, L. M., Sauerbrei, W., & Taube, S. E. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001216 · Cited by 1,013
The Prognostic Role of a Gene Signature from Tumorigenic Breast-Cancer Cells
Liu, R., Wang, X., Chen, G. Y., Dalerba, P., Gurney, A., Hoey, T., Sherlock, G., Lewicki, J., Shedden, K., & Clarke, M. F. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063994 · Cited by 985
Self-citationMerlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., et al. (2011) · Cell Stem Cell · doi:10.1016/j.stem.2011.02.020 · Cited by 934
Systemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
De Sousa E Melo, F., Wang, X., Jansen, M., Fessler, E., Trinh, A., de Rooij, L. P. M. H., de Jong, J. H., de Boer, O. J., van Leersum, R., Bijlsma, M. F., et al. (2013) · Nature Medicine · doi:10.1038/nm.3174 · Cited by 771
Smith, J. J., Deane, N. G., Wu, F., Merchant, N. B., Zhang, B., Jiang, A., Lu, P., Johnson, J. C., Schmidt, C., Bailey, C. E., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.005 · Cited by 716
Single-cell dissection of transcriptional heterogeneity in human colon tumors
Dalerba, P., Kalisky, T., Sahoo, D., Rajendran, P. S., Rothenberg, M. E., Leyrat, A. A., Sim, S., Okamoto, J., Johnston, D. M., Qian, D., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.2038 · Cited by 703
Self-citationHomeosis and intestinal tumours in Cdx2 mutant mice
Chawengsaksophak, K., James, R., Hammond, V. E., Köntgen, F., & Beck, F. (1997) · Nature · doi:10.1038/386084a0 · Cited by 672
American Joint Committee on Cancer prognostic factors consensus conference: Colorectal working group
Compton, C., Fenoglio-Preiser, C. M., Pettigrew, N., & Fielding, L. P. (2000) · Cancer · doi:10.1002/(sici)1097-0142(20000401)88:7<1739::aid-cncr30>3.0.co;2-t · Cited by 599
Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer
Wang, Y., Jatkoe, T., Zhang, Y., Mutch, M. G., Talantov, D., Jiang, J., McLeod, H. L., & Atkins, D. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.186 · Cited by 460
Adjuvant Chemotherapy for Stage II Colon Cancer With Poor Prognostic Features
O'Connor, E. S., Greenblatt, D. Y., LoConte, N. K., Gangnon, R. E., Liou, J.-I., Heise, C. P., & Smith, M. A. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3426 · Cited by 451
Jorissen, R. N., Gibbs, P., Christie, M., Prakash, S., Lipton, L., Desai, J., Kerr, D., Aaltonen, L. A., Arango, D., Kruhøffer, M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1431 · Cited by 437
ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival
Weichert, W., Knösel, T., Bellach, J., Dietel, M., & Kristiansen, G. (2004) · Journal of Clinical Pathology · doi:10.1136/jcp.2004.016238 · Cited by 264
Hinoi, T., Tani, M., Lucas, P. C., Caca, K., Dunn, R. L., Macri, E., Loda, M., Appelman, H. D., Cho, K. R., & Fearon, E. R. (2001) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63074-x · Cited by 225
Stage II Colon Cancer Prognosis Prediction by Tumor Gene Expression Profiling
Barrier, A., Boelle, P.-Y., Roser, F., Gregg, J., Tse, C., Brault, D., Lacaine, F., Houry, S., Huguier, M., Franc, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0229 · Cited by 214
Levin, T. G., Powell, A. E., Davies, P. S., Silk, A. D., Dismuke, A. D., Anderson, E. C., Swain, J. R., & Wong, M. H. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.08.053 · Cited by 191
Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal Cancer
Baba, Y., Nosho, K., Shima, K., Freed, E., Irahara, N., Philips, J., Meyerhardt, J. A., Hornick, J. L., Shivdasani, R. A., Fuchs, C. S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0401 · Cited by 181
Yothers, G., O'Connell, M. J., Lee, M., Lopatin, M., Clark-Langone, K. M., Millward, C., Paik, S., Sharif, S., Shak, S., & Wolmark, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3116 · Cited by 173
Self-citationZlobec, I., Bihl, M. P., Schwarb, H., Terracciano, L., & Lugli, A. (2010) · International Journal of Cancer · doi:10.1002/ijc.25042 · Cited by 172
Lugli, A., Tzankov, A., Zlobec, I., & Terracciano, L. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.117 · Cited by 156
Extracting binary signals from microarray time-course data
Sahoo, D., Dill, D. L., Tibshirani, R. J., & Plevritis, S. K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm284 · Cited by 150
Self-citationLoss of CDX2 expression is associated with poor prognosis in colorectal cancer patients
Bae, J. M. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i5.1457 · Cited by 129
Boolean implication networks derived from large scale, whole genome microarray datasets
Sahoo, D., Dill, D. L., Gentles, A. J., Tibshirani, R. J., & Plevritis, S. K. (2008) · Genome biology · doi:10.1186/gb-2008-9-10-r157 · Cited by 115
Self-citationZlobec, I., Kovac, M. B., Erzberger, P., Molinari, F., Bihl, M., Rufle, A., Foerster, A., Frattini, M., Terracciano, L., Heinimann, K., et al. (2010) · International Journal of Cancer · doi:10.1002/ijc.25265 · Cited by 108
A Seven-Gene Signature Aggregates a Subgroup of Stage II Colon Cancers with Stage III
Laibe, S., Lagarde, A., Ferrari, A., Monges, G. M., Birnbaum, D., & Olschwang, S. (2012) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2012.0039 · Cited by 82
The role of Cdx genes in the gut and in axial development
Beck, F., & Stringer, E. J. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380353 · Cited by 70
Dilemma of Stage II Colon Cancer and Decision Making for Adjuvant Chemotherapy
Fang, S. H., Efron, J. E., Berho, M. E., & Wexner, S. D. (2014) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.09.010 · Cited by 66
Molecular profiles and clinical outcome of stage UICC II colon cancer patients
Gröne, J., Lenze, D., Jurinović, V., Hummel, M., Seidel, H., Leder, G., Beckmann, G., Sommer, A., Grützmann, R., Pilarsky, C. P., et al. (2011) · International Journal of Colorectal Disease · doi:10.1007/s00384-011-1176-x · Cited by 49
Ongoing Challenge of Stage II Colon Cancer
Meropol, N. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.4571 · Cited by 35
Cited by
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 4,974
From tumour heterogeneity to advances in precision treatment of colorectal cancer
Punt, C. J. A., Koopman, M., & Vermeulen, L. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.171 · Cited by 654
Fusobacterium nucleatum promotes colorectal cancer by inducing Wnt/β‐catenin modulator Annexin A1
Rubinstein, M. R., Baik, J. E., Lagana, S. M., Han, R. P., Raab, W. J., Sahoo, D., Dalerba, P., Wang, T. C., & Han, Y. W. (2019) · EMBO reports · doi:10.15252/embr.201847638 · Cited by 525
Self-citationLongo, D. L., & Drazen, J. M. (2016) · New England Journal of Medicine · doi:10.1056/nejme1516564 · Cited by 419
Vogel, J. D., Felder, S. I., Bhama, A. R., Hawkins, A. T., Langenfeld, S. J., Shaffer, V. O., Thorsen, A. J., Weiser, M. R., Chang, G. J., Lightner, A. L., et al. (2022) · Diseases of the Colon & Rectum · doi:10.1097/dcr.0000000000002323 · Cited by 401
Metadata
- Authors
- Dalerba, P., Sahoo, D., Paik, S., Guo, X., Yothers, G., Song, N., Wilcox-Fogel, N., Forgó, E., Rajendran, P. S., Miranda, S. P., Hisamori, S., Hutchison, J., Kalisky, T., Qian, D., Wolmark, N., Fisher, G. A., van de Rijn, M., & Clarke, M. F.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-01-21
- Volume
- 374
- Issue
- 3
- Pages
- 211-222
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2301536592
- Cited by
- 470
- References
- 34
- FWCI
- 32.45
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.